patient_id
stringlengths 20
20
| cancer_type
stringclasses 1
value | histology
stringclasses 2
values | stage_at_diagnosis
stringclasses 2
values | molecular_profile
dict | baseline_clinical
dict | disease_burden_at_dx
dict | treatment_course
dict | survival_outcomes
dict | longitudinal_labs
listlengths 3
3
| synthetic_high_fidelity
bool 1
class |
|---|---|---|---|---|---|---|---|---|---|---|
ANODE_SYNTH_2025_001
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "KRAS G12C",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.1
}
|
{
"age": 76,
"bmi": 22.5,
"comorbidities": [
"hypertension",
"diabetes"
],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 39
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"pleura",
"brain",
"bone"
],
"primary_tumor_size_cm": 4,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 18,
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -73
},
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-01-28"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-05-29",
"toxicity_grade": [
"Grade 2 fatigue",
"none"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 67
}
|
[
{
"alt_U_L": 39,
"creatinine_mg_dL": 1.1,
"date": "2024-12-03",
"hemoglobin_g_dL": 13,
"platelets_k_uL": 349,
"wbc_k_uL": 8.2
},
{
"alt_U_L": 118,
"creatinine_mg_dL": 0.9400000000000001,
"date": "2025-07-27",
"hemoglobin_g_dL": 12.3,
"platelets_k_uL": 171,
"wbc_k_uL": 8.4
},
{
"alt_U_L": 184,
"creatinine_mg_dL": 1.43,
"date": "2026-05-29",
"hemoglobin_g_dL": 12.5,
"platelets_k_uL": 251,
"wbc_k_uL": 4
}
] | true
|
ANODE_SYNTH_2025_002
|
Non-small cell lung cancer
|
Squamous cell
|
IV
|
{
"driver_mutation": "None (PD-L1 high)",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 53,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8
}
|
{
"age": 69,
"bmi": 30.2,
"comorbidities": [
"diabetes",
"hyperlipidemia"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 32
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"liver",
"brain",
"contralateral lung"
],
"primary_tumor_size_cm": 5.8,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 10,
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -78
},
"regimen": "pembrolizumab 200 mg q3w",
"start_date": "2024-02-04"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "docetaxel 75 mg/m² q21d",
"start_date": "2025-04-21",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": true,
"overall_survival_months": 30
}
|
[
{
"alt_U_L": 53,
"creatinine_mg_dL": 0.91,
"date": "2024-01-15",
"hemoglobin_g_dL": 14,
"platelets_k_uL": 439,
"wbc_k_uL": 5.2
},
{
"alt_U_L": 36,
"creatinine_mg_dL": 1.15,
"date": "2024-08-02",
"hemoglobin_g_dL": 10.8,
"platelets_k_uL": 187,
"wbc_k_uL": 5.1
},
{
"alt_U_L": 36,
"creatinine_mg_dL": 1.94,
"date": "2025-04-21",
"hemoglobin_g_dL": 9.7,
"platelets_k_uL": 179,
"wbc_k_uL": 5.6
}
] | true
|
ANODE_SYNTH_2025_003
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR exon 19 deletion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.8
}
|
{
"age": 78,
"bmi": 35.6,
"comorbidities": [],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"primary_tumor_size_cm": 5.2,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 27,
"radiologic_response": {
"first_ct_8wk_change_percent": -13,
"peak_response_20wk_change_percent": -30
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2021-03-21"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-12-27",
"toxicity_grade": [
"none",
"Grade 3 neutropenia"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 38
}
|
[
{
"alt_U_L": 14,
"creatinine_mg_dL": 0.89,
"date": "2021-02-16",
"hemoglobin_g_dL": 12.6,
"platelets_k_uL": 274,
"wbc_k_uL": 4.6
},
{
"alt_U_L": 99,
"creatinine_mg_dL": 1.21,
"date": "2021-09-17",
"hemoglobin_g_dL": 12.4,
"platelets_k_uL": 142,
"wbc_k_uL": 6.8
},
{
"alt_U_L": 97,
"creatinine_mg_dL": 1.5,
"date": "2022-12-27",
"hemoglobin_g_dL": 10.5,
"platelets_k_uL": 268,
"wbc_k_uL": 4.7
}
] | true
|
ANODE_SYNTH_2025_004
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.7
}
|
{
"age": 53,
"bmi": 22.1,
"comorbidities": [
"diabetes"
],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"contralateral lung",
"brain"
],
"primary_tumor_size_cm": 3.4,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 20,
"radiologic_response": {
"first_ct_8wk_change_percent": -26,
"peak_response_20wk_change_percent": -68
},
"regimen": "alectinib 600 mg BID",
"start_date": "2025-08-29"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-01-24",
"toxicity_grade": [
"Grade 2 fatigue",
"Grade 3 neutropenia"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 32
}
|
[
{
"alt_U_L": 69,
"creatinine_mg_dL": 0.67,
"date": "2025-08-04",
"hemoglobin_g_dL": 13.1,
"platelets_k_uL": 252,
"wbc_k_uL": 9.1
},
{
"alt_U_L": 58,
"creatinine_mg_dL": 1.12,
"date": "2026-02-25",
"hemoglobin_g_dL": 13.9,
"platelets_k_uL": 229,
"wbc_k_uL": 7.8
},
{
"alt_U_L": 178,
"creatinine_mg_dL": 1.8599999999999999,
"date": "2028-01-24",
"hemoglobin_g_dL": 10.4,
"platelets_k_uL": 137,
"wbc_k_uL": 4.9
}
] | true
|
ANODE_SYNTH_2025_005
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR L858R",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17
}
|
{
"age": 57,
"bmi": 25.8,
"comorbidities": [],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain",
"contralateral lung",
"bone"
],
"primary_tumor_size_cm": 7.6,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 36,
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -70
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2025-12-14"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-03-10",
"toxicity_grade": [
"Grade 3 neutropenia",
"none"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": false,
"overall_survival_months": 72
}
|
[
{
"alt_U_L": 72,
"creatinine_mg_dL": 0.64,
"date": "2025-11-11",
"hemoglobin_g_dL": 13.3,
"platelets_k_uL": 321,
"wbc_k_uL": 5.8
},
{
"alt_U_L": 41,
"creatinine_mg_dL": 1.5899999999999999,
"date": "2026-06-12",
"hemoglobin_g_dL": 12.4,
"platelets_k_uL": 140,
"wbc_k_uL": 6.9
},
{
"alt_U_L": 112,
"creatinine_mg_dL": 1.33,
"date": "2028-03-10",
"hemoglobin_g_dL": 9.8,
"platelets_k_uL": 133,
"wbc_k_uL": 7.1
}
] | true
|
ANODE_SYNTH_2025_006
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "KRAS G12C",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.7
}
|
{
"age": 68,
"bmi": 26.5,
"comorbidities": [],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 38
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"pleura"
],
"primary_tumor_size_cm": 7.2,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 16,
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -27
},
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-06-01"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-09-03",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 3 neutropenia"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 90
}
|
[
{
"alt_U_L": 20,
"creatinine_mg_dL": 1.21,
"date": "2021-05-10",
"hemoglobin_g_dL": 15.3,
"platelets_k_uL": 158,
"wbc_k_uL": 8.1
},
{
"alt_U_L": 114,
"creatinine_mg_dL": 0.96,
"date": "2021-11-28",
"hemoglobin_g_dL": 13.6,
"platelets_k_uL": 243,
"wbc_k_uL": 6.3
},
{
"alt_U_L": 200,
"creatinine_mg_dL": 0.81,
"date": "2023-09-03",
"hemoglobin_g_dL": 11.7,
"platelets_k_uL": 254,
"wbc_k_uL": 5.4
}
] | true
|
ANODE_SYNTH_2025_007
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR exon 19 deletion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.7
}
|
{
"age": 84,
"bmi": 20.6,
"comorbidities": [
"hyperlipidemia",
"COPD"
],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain"
],
"primary_tumor_size_cm": 3,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 20,
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -54
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2021-12-22"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-07-25",
"toxicity_grade": [
"Grade 2 fatigue",
"Grade 3 neutropenia"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": true,
"overall_survival_months": 73
}
|
[
{
"alt_U_L": 23,
"creatinine_mg_dL": 1.09,
"date": "2021-11-14",
"hemoglobin_g_dL": 12.7,
"platelets_k_uL": 228,
"wbc_k_uL": 10.8
},
{
"alt_U_L": 22,
"creatinine_mg_dL": 1.5899999999999999,
"date": "2022-06-20",
"hemoglobin_g_dL": 10.7,
"platelets_k_uL": 305,
"wbc_k_uL": 7.6
},
{
"alt_U_L": 196,
"creatinine_mg_dL": 1.3,
"date": "2023-07-25",
"hemoglobin_g_dL": 11.2,
"platelets_k_uL": 249,
"wbc_k_uL": 4.3
}
] | true
|
ANODE_SYNTH_2025_008
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "None (PD-L1 high)",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 89,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.1
}
|
{
"age": 81,
"bmi": 24.4,
"comorbidities": [
"COPD"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 30
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"adrenal",
"liver"
],
"primary_tumor_size_cm": 4.4,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 6,
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -79
},
"regimen": "pembrolizumab 200 mg q3w",
"start_date": "2025-02-18"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "docetaxel 75 mg/m² q21d",
"start_date": "2026-11-14",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 3 neutropenia"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": false,
"overall_survival_months": 41
}
|
[
{
"alt_U_L": 50,
"creatinine_mg_dL": 1.22,
"date": "2025-01-11",
"hemoglobin_g_dL": 15.2,
"platelets_k_uL": 245,
"wbc_k_uL": 7
},
{
"alt_U_L": 57,
"creatinine_mg_dL": 1.3900000000000001,
"date": "2025-08-17",
"hemoglobin_g_dL": 10.3,
"platelets_k_uL": 336,
"wbc_k_uL": 8.8
},
{
"alt_U_L": 145,
"creatinine_mg_dL": 1.42,
"date": "2026-11-14",
"hemoglobin_g_dL": 10.4,
"platelets_k_uL": 236,
"wbc_k_uL": 6.6
}
] | true
|
ANODE_SYNTH_2025_009
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "KRAS G12C",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.2
}
|
{
"age": 82,
"bmi": 33.9,
"comorbidities": [],
"ecog_performance_status": 2,
"sex": "female",
"smoking_pack_years": 22
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"pleura",
"adrenal"
],
"primary_tumor_size_cm": 5.5,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 17,
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -41
},
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-06-13"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-03-28",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": true,
"overall_survival_months": 34
}
|
[
{
"alt_U_L": 72,
"creatinine_mg_dL": 0.87,
"date": "2024-05-16",
"hemoglobin_g_dL": 12.7,
"platelets_k_uL": 388,
"wbc_k_uL": 10.5
},
{
"alt_U_L": 108,
"creatinine_mg_dL": 0.77,
"date": "2024-12-10",
"hemoglobin_g_dL": 13.4,
"platelets_k_uL": 349,
"wbc_k_uL": 4
},
{
"alt_U_L": 144,
"creatinine_mg_dL": 0.97,
"date": "2026-03-28",
"hemoglobin_g_dL": 11,
"platelets_k_uL": 198,
"wbc_k_uL": 6.1
}
] | true
|
ANODE_SYNTH_2025_010
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR L858R",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.2
}
|
{
"age": 83,
"bmi": 30.3,
"comorbidities": [
"diabetes"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain"
],
"primary_tumor_size_cm": 4.7,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 15,
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -55
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2021-03-10"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-05-14",
"toxicity_grade": [
"none",
"Grade 2 fatigue"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": false,
"overall_survival_months": 70
}
|
[
{
"alt_U_L": 60,
"creatinine_mg_dL": 0.81,
"date": "2021-01-12",
"hemoglobin_g_dL": 14.1,
"platelets_k_uL": 221,
"wbc_k_uL": 7.5
},
{
"alt_U_L": 49,
"creatinine_mg_dL": 1.09,
"date": "2021-09-06",
"hemoglobin_g_dL": 10.8,
"platelets_k_uL": 317,
"wbc_k_uL": 9
},
{
"alt_U_L": 109,
"creatinine_mg_dL": 0.8,
"date": "2023-05-14",
"hemoglobin_g_dL": 12.8,
"platelets_k_uL": 276,
"wbc_k_uL": 5.8
}
] | true
|
ANODE_SYNTH_2025_011
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR exon 19 deletion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.6
}
|
{
"age": 49,
"bmi": 31.1,
"comorbidities": [],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"pleura",
"bone"
],
"primary_tumor_size_cm": 3.1,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 18,
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -22
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2023-07-12"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-01-05",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 3 neutropenia"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 46
}
|
[
{
"alt_U_L": 13,
"creatinine_mg_dL": 1.03,
"date": "2023-06-22",
"hemoglobin_g_dL": 14.1,
"platelets_k_uL": 314,
"wbc_k_uL": 4.8
},
{
"alt_U_L": 44,
"creatinine_mg_dL": 1.42,
"date": "2024-01-08",
"hemoglobin_g_dL": 10.6,
"platelets_k_uL": 237,
"wbc_k_uL": 6.9
},
{
"alt_U_L": 119,
"creatinine_mg_dL": 1.4100000000000001,
"date": "2025-01-05",
"hemoglobin_g_dL": 12.4,
"platelets_k_uL": 171,
"wbc_k_uL": 4.6
}
] | true
|
ANODE_SYNTH_2025_012
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "BRAF V600E",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.5
}
|
{
"age": 74,
"bmi": 22.3,
"comorbidities": [
"hyperlipidemia"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 17
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"liver"
],
"primary_tumor_size_cm": 7.9,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 13,
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -51
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-12-16"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2025-06-06",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": false,
"overall_survival_months": 46
}
|
[
{
"alt_U_L": 62,
"creatinine_mg_dL": 0.75,
"date": "2023-11-18",
"hemoglobin_g_dL": 15.3,
"platelets_k_uL": 182,
"wbc_k_uL": 10.6
},
{
"alt_U_L": 93,
"creatinine_mg_dL": 0.81,
"date": "2024-06-13",
"hemoglobin_g_dL": 11.5,
"platelets_k_uL": 316,
"wbc_k_uL": 7.5
},
{
"alt_U_L": 156,
"creatinine_mg_dL": 1.53,
"date": "2025-06-06",
"hemoglobin_g_dL": 12.8,
"platelets_k_uL": 287,
"wbc_k_uL": 7.4
}
] | true
|
ANODE_SYNTH_2025_013
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 1.9
}
|
{
"age": 68,
"bmi": 29.1,
"comorbidities": [
"hypertension"
],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": true,
"metastatic_sites": [
"adrenal",
"bone"
],
"primary_tumor_size_cm": 4.5,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 30,
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -23
},
"regimen": "alectinib 600 mg BID",
"start_date": "2024-06-22"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-10-05",
"toxicity_grade": [
"none",
"Grade 3 neutropenia"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 69
}
|
[
{
"alt_U_L": 35,
"creatinine_mg_dL": 0.68,
"date": "2024-04-27",
"hemoglobin_g_dL": 12.6,
"platelets_k_uL": 220,
"wbc_k_uL": 9.8
},
{
"alt_U_L": 24,
"creatinine_mg_dL": 1.49,
"date": "2024-12-19",
"hemoglobin_g_dL": 12.5,
"platelets_k_uL": 194,
"wbc_k_uL": 7.2
},
{
"alt_U_L": 30,
"creatinine_mg_dL": 1.4100000000000001,
"date": "2026-10-05",
"hemoglobin_g_dL": 13,
"platelets_k_uL": 162,
"wbc_k_uL": 5.9
}
] | true
|
ANODE_SYNTH_2025_014
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR exon 19 deletion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.5
}
|
{
"age": 69,
"bmi": 24.9,
"comorbidities": [],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain",
"liver"
],
"primary_tumor_size_cm": 4.5,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Stable disease",
"pfs_months": 28,
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -27
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2022-09-30"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-02-01",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "new brain metastases"
}
}
|
{
"censored": true,
"overall_survival_months": 76
}
|
[
{
"alt_U_L": 33,
"creatinine_mg_dL": 1,
"date": "2022-08-27",
"hemoglobin_g_dL": 15,
"platelets_k_uL": 251,
"wbc_k_uL": 10.5
},
{
"alt_U_L": 119,
"creatinine_mg_dL": 1.08,
"date": "2023-03-29",
"hemoglobin_g_dL": 10.5,
"platelets_k_uL": 225,
"wbc_k_uL": 5.9
},
{
"alt_U_L": 151,
"creatinine_mg_dL": 1.87,
"date": "2024-02-01",
"hemoglobin_g_dL": 9.6,
"platelets_k_uL": 214,
"wbc_k_uL": 4.2
}
] | true
|
ANODE_SYNTH_2025_015
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.1
}
|
{
"age": 51,
"bmi": 35.5,
"comorbidities": [],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"adrenal"
],
"primary_tumor_size_cm": 4.7,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 36,
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -23
},
"regimen": "alectinib 600 mg BID",
"start_date": "2021-05-24"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-08-21",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 80
}
|
[
{
"alt_U_L": 43,
"creatinine_mg_dL": 1.19,
"date": "2021-04-10",
"hemoglobin_g_dL": 13,
"platelets_k_uL": 186,
"wbc_k_uL": 8.1
},
{
"alt_U_L": 118,
"creatinine_mg_dL": 1.29,
"date": "2021-11-20",
"hemoglobin_g_dL": 13.7,
"platelets_k_uL": 149,
"wbc_k_uL": 8
},
{
"alt_U_L": 33,
"creatinine_mg_dL": 1.1,
"date": "2022-08-21",
"hemoglobin_g_dL": 12.3,
"platelets_k_uL": 220,
"wbc_k_uL": 6.4
}
] | true
|
ANODE_SYNTH_2025_016
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "BRAF V600E",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8
}
|
{
"age": 70,
"bmi": 20.4,
"comorbidities": [
"diabetes",
"COPD"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 56
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"primary_tumor_size_cm": 7.5,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 14,
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -21
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-10-11"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2028-03-16",
"toxicity_grade": [
"Grade 2 fatigue",
"none"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 94
}
|
[
{
"alt_U_L": 64,
"creatinine_mg_dL": 0.79,
"date": "2025-08-12",
"hemoglobin_g_dL": 15,
"platelets_k_uL": 251,
"wbc_k_uL": 8.6
},
{
"alt_U_L": 45,
"creatinine_mg_dL": 1.3,
"date": "2026-04-09",
"hemoglobin_g_dL": 11.3,
"platelets_k_uL": 324,
"wbc_k_uL": 5.6
},
{
"alt_U_L": 193,
"creatinine_mg_dL": 1.01,
"date": "2028-03-16",
"hemoglobin_g_dL": 10.6,
"platelets_k_uL": 319,
"wbc_k_uL": 5.9
}
] | true
|
ANODE_SYNTH_2025_017
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "None (PD-L1 high)",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8
}
|
{
"age": 66,
"bmi": 31.5,
"comorbidities": [
"diabetes"
],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 23
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"pleura"
],
"primary_tumor_size_cm": 6.6,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 8,
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -44
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-08-13"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2022-12-22",
"toxicity_grade": [
"Grade 3 neutropenia",
"Grade 2 fatigue"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 89
}
|
[
{
"alt_U_L": 26,
"creatinine_mg_dL": 1.22,
"date": "2021-06-25",
"hemoglobin_g_dL": 12.6,
"platelets_k_uL": 357,
"wbc_k_uL": 7.1
},
{
"alt_U_L": 106,
"creatinine_mg_dL": 1.53,
"date": "2022-02-09",
"hemoglobin_g_dL": 11.4,
"platelets_k_uL": 186,
"wbc_k_uL": 4.2
},
{
"alt_U_L": 94,
"creatinine_mg_dL": 1.87,
"date": "2022-12-22",
"hemoglobin_g_dL": 9.7,
"platelets_k_uL": 164,
"wbc_k_uL": 6.3
}
] | true
|
ANODE_SYNTH_2025_018
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "BRAF V600E",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.4
}
|
{
"age": 53,
"bmi": 18.7,
"comorbidities": [],
"ecog_performance_status": 0,
"sex": "male",
"smoking_pack_years": 43
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"contralateral lung",
"bone",
"pleura"
],
"primary_tumor_size_cm": 7.3,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 17,
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -61
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-03-16"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-03-01",
"toxicity_grade": [
"Grade 2 fatigue",
"Grade 1 nausea"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 41
}
|
[
{
"alt_U_L": 62,
"creatinine_mg_dL": 1.06,
"date": "2024-02-26",
"hemoglobin_g_dL": 14.1,
"platelets_k_uL": 199,
"wbc_k_uL": 6.2
},
{
"alt_U_L": 86,
"creatinine_mg_dL": 1.2,
"date": "2024-09-12",
"hemoglobin_g_dL": 10,
"platelets_k_uL": 225,
"wbc_k_uL": 5.2
},
{
"alt_U_L": 154,
"creatinine_mg_dL": 1.32,
"date": "2026-03-01",
"hemoglobin_g_dL": 11.1,
"platelets_k_uL": 326,
"wbc_k_uL": 5.2
}
] | true
|
ANODE_SYNTH_2025_019
|
Non-small cell lung cancer
|
Squamous cell
|
IV
|
{
"driver_mutation": "None (PD-L1 high)",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 51,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.6
}
|
{
"age": 51,
"bmi": 22.2,
"comorbidities": [],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 30
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"adrenal"
],
"primary_tumor_size_cm": 4.3,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Complete response",
"pfs_months": 8,
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -66
},
"regimen": "pembrolizumab 200 mg q3w",
"start_date": "2022-11-04"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "docetaxel 75 mg/m² q21d",
"start_date": "2025-03-16",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 fatigue"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 32
}
|
[
{
"alt_U_L": 80,
"creatinine_mg_dL": 0.88,
"date": "2022-10-06",
"hemoglobin_g_dL": 12.2,
"platelets_k_uL": 393,
"wbc_k_uL": 10.6
},
{
"alt_U_L": 32,
"creatinine_mg_dL": 1.01,
"date": "2023-05-03",
"hemoglobin_g_dL": 12.3,
"platelets_k_uL": 175,
"wbc_k_uL": 6
},
{
"alt_U_L": 47,
"creatinine_mg_dL": 0.91,
"date": "2025-03-16",
"hemoglobin_g_dL": 11.2,
"platelets_k_uL": 157,
"wbc_k_uL": 3.5
}
] | true
|
ANODE_SYNTH_2025_020
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 3,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.1
}
|
{
"age": 52,
"bmi": 34.1,
"comorbidities": [
"none",
"diabetes"
],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain",
"pleura",
"liver"
],
"primary_tumor_size_cm": 7.3,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 38,
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -61
},
"regimen": "alectinib 600 mg BID",
"start_date": "2024-12-24"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-02-26",
"toxicity_grade": [
"Grade 2 fatigue",
"none"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 64
}
|
[
{
"alt_U_L": 38,
"creatinine_mg_dL": 1.08,
"date": "2024-11-08",
"hemoglobin_g_dL": 14.9,
"platelets_k_uL": 193,
"wbc_k_uL": 8.6
},
{
"alt_U_L": 113,
"creatinine_mg_dL": 1.38,
"date": "2025-06-22",
"hemoglobin_g_dL": 11.5,
"platelets_k_uL": 237,
"wbc_k_uL": 7.8
},
{
"alt_U_L": 180,
"creatinine_mg_dL": 2,
"date": "2026-02-26",
"hemoglobin_g_dL": 10.7,
"platelets_k_uL": 202,
"wbc_k_uL": 3.2
}
] | true
|
ANODE_SYNTH_2025_021
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "None (PD-L1 high)",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 42,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.5
}
|
{
"age": 66,
"bmi": 29.3,
"comorbidities": [
"hypertension"
],
"ecog_performance_status": 0,
"sex": "female",
"smoking_pack_years": 22
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"adrenal",
"bone",
"contralateral lung"
],
"primary_tumor_size_cm": 6.1,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 7,
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -76
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-05-29"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-03-30",
"toxicity_grade": [
"none",
"Grade 1 nausea"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 87
}
|
[
{
"alt_U_L": 54,
"creatinine_mg_dL": 1.09,
"date": "2024-05-04",
"hemoglobin_g_dL": 14.2,
"platelets_k_uL": 316,
"wbc_k_uL": 6
},
{
"alt_U_L": 32,
"creatinine_mg_dL": 1.25,
"date": "2024-11-25",
"hemoglobin_g_dL": 12.4,
"platelets_k_uL": 253,
"wbc_k_uL": 4.6
},
{
"alt_U_L": 151,
"creatinine_mg_dL": 1.32,
"date": "2026-03-30",
"hemoglobin_g_dL": 11.4,
"platelets_k_uL": 243,
"wbc_k_uL": 5.5
}
] | true
|
ANODE_SYNTH_2025_022
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "ROS1 fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.1
}
|
{
"age": 68,
"bmi": 37.8,
"comorbidities": [
"none"
],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 12
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"pleura",
"liver"
],
"primary_tumor_size_cm": 3.6,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 17,
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -26
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-10-01"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2027-12-28",
"toxicity_grade": [
"Grade 3 neutropenia",
"Grade 2 fatigue"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 53
}
|
[
{
"alt_U_L": 11,
"creatinine_mg_dL": 1.2,
"date": "2025-08-04",
"hemoglobin_g_dL": 15.1,
"platelets_k_uL": 174,
"wbc_k_uL": 9.4
},
{
"alt_U_L": 48,
"creatinine_mg_dL": 1.24,
"date": "2026-03-30",
"hemoglobin_g_dL": 13.3,
"platelets_k_uL": 234,
"wbc_k_uL": 7.4
},
{
"alt_U_L": 187,
"creatinine_mg_dL": 1.09,
"date": "2027-12-28",
"hemoglobin_g_dL": 11.1,
"platelets_k_uL": 143,
"wbc_k_uL": 4.9
}
] | true
|
ANODE_SYNTH_2025_023
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13.1
}
|
{
"age": 51,
"bmi": 33.8,
"comorbidities": [],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": true,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"primary_tumor_size_cm": 4.9,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Stable disease",
"pfs_months": 16,
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -58
},
"regimen": "alectinib 600 mg BID",
"start_date": "2021-09-06"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-12-19",
"toxicity_grade": [
"Grade 1 nausea",
"none"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 60
}
|
[
{
"alt_U_L": 40,
"creatinine_mg_dL": 0.97,
"date": "2021-08-20",
"hemoglobin_g_dL": 14.9,
"platelets_k_uL": 273,
"wbc_k_uL": 4.8
},
{
"alt_U_L": 34,
"creatinine_mg_dL": 1.38,
"date": "2022-03-05",
"hemoglobin_g_dL": 11.7,
"platelets_k_uL": 334,
"wbc_k_uL": 8.3
},
{
"alt_U_L": 178,
"creatinine_mg_dL": 1.53,
"date": "2023-12-19",
"hemoglobin_g_dL": 11.4,
"platelets_k_uL": 116,
"wbc_k_uL": 6.3
}
] | true
|
ANODE_SYNTH_2025_024
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.2
}
|
{
"age": 62,
"bmi": 33.8,
"comorbidities": [
"none",
"hypertension"
],
"ecog_performance_status": 1,
"sex": "male",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"contralateral lung",
"bone"
],
"primary_tumor_size_cm": 3.7,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 29,
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -60
},
"regimen": "alectinib 600 mg BID",
"start_date": "2022-01-08"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-11-14",
"toxicity_grade": [
"Grade 3 neutropenia",
"none"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 36
}
|
[
{
"alt_U_L": 16,
"creatinine_mg_dL": 0.73,
"date": "2021-11-13",
"hemoglobin_g_dL": 12.9,
"platelets_k_uL": 267,
"wbc_k_uL": 9
},
{
"alt_U_L": 62,
"creatinine_mg_dL": 0.75,
"date": "2022-07-07",
"hemoglobin_g_dL": 11,
"platelets_k_uL": 136,
"wbc_k_uL": 7.4
},
{
"alt_U_L": 23,
"creatinine_mg_dL": 1.6600000000000001,
"date": "2023-11-14",
"hemoglobin_g_dL": 10.3,
"platelets_k_uL": 231,
"wbc_k_uL": 7.5
}
] | true
|
ANODE_SYNTH_2025_025
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "ROS1 fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.3
}
|
{
"age": 64,
"bmi": 27.2,
"comorbidities": [
"COPD"
],
"ecog_performance_status": 2,
"sex": "male",
"smoking_pack_years": 26
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"pleura",
"adrenal",
"brain"
],
"primary_tumor_size_cm": 7.5,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Complete response",
"pfs_months": 13,
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -26
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-05-26"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-09-21",
"toxicity_grade": [
"Grade 1 nausea",
"Grade 2 fatigue"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 40
}
|
[
{
"alt_U_L": 29,
"creatinine_mg_dL": 1.07,
"date": "2022-04-05",
"hemoglobin_g_dL": 14.1,
"platelets_k_uL": 382,
"wbc_k_uL": 7.1
},
{
"alt_U_L": 36,
"creatinine_mg_dL": 1.38,
"date": "2022-11-22",
"hemoglobin_g_dL": 12.2,
"platelets_k_uL": 233,
"wbc_k_uL": 6.3
},
{
"alt_U_L": 67,
"creatinine_mg_dL": 1.97,
"date": "2023-09-21",
"hemoglobin_g_dL": 11.8,
"platelets_k_uL": 238,
"wbc_k_uL": 7.3
}
] | true
|
ANODE_SYNTH_2025_026
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.3
}
|
{
"age": 81,
"bmi": 22.8,
"comorbidities": [
"COPD"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"liver",
"adrenal",
"brain"
],
"primary_tumor_size_cm": 6.2,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 30,
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -43
},
"regimen": "alectinib 600 mg BID",
"start_date": "2022-11-29"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2024-04-15",
"toxicity_grade": [
"none",
"Grade 3 neutropenia"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 68
}
|
[
{
"alt_U_L": 77,
"creatinine_mg_dL": 0.84,
"date": "2022-10-03",
"hemoglobin_g_dL": 14.3,
"platelets_k_uL": 199,
"wbc_k_uL": 7
},
{
"alt_U_L": 86,
"creatinine_mg_dL": 1.33,
"date": "2023-05-28",
"hemoglobin_g_dL": 13.4,
"platelets_k_uL": 225,
"wbc_k_uL": 8.8
},
{
"alt_U_L": 112,
"creatinine_mg_dL": 1.9100000000000001,
"date": "2024-04-15",
"hemoglobin_g_dL": 12.8,
"platelets_k_uL": 277,
"wbc_k_uL": 7
}
] | true
|
ANODE_SYNTH_2025_027
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "ALK fusion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.8
}
|
{
"age": 51,
"bmi": 32.6,
"comorbidities": [
"diabetes",
"hyperlipidemia"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"brain",
"liver"
],
"primary_tumor_size_cm": 8,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Partial response",
"pfs_months": 32,
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -33
},
"regimen": "alectinib 600 mg BID",
"start_date": "2024-07-04"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-08-29",
"toxicity_grade": [
"none",
"Grade 1 nausea"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 94
}
|
[
{
"alt_U_L": 12,
"creatinine_mg_dL": 1.13,
"date": "2024-06-08",
"hemoglobin_g_dL": 13.4,
"platelets_k_uL": 366,
"wbc_k_uL": 9.3
},
{
"alt_U_L": 19,
"creatinine_mg_dL": 1.55,
"date": "2024-12-31",
"hemoglobin_g_dL": 10.1,
"platelets_k_uL": 132,
"wbc_k_uL": 4.8
},
{
"alt_U_L": 126,
"creatinine_mg_dL": 1.49,
"date": "2026-08-29",
"hemoglobin_g_dL": 12.6,
"platelets_k_uL": 144,
"wbc_k_uL": 6
}
] | true
|
ANODE_SYNTH_2025_028
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "KRAS G12C",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.9
}
|
{
"age": 58,
"bmi": 32.1,
"comorbidities": [
"hypertension",
"COPD"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 44
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"liver"
],
"primary_tumor_size_cm": 4.1,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Stable disease",
"pfs_months": 13,
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -60
},
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-01-26"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-07-31",
"toxicity_grade": [
"Grade 3 neutropenia",
"Grade 1 nausea"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 60
}
|
[
{
"alt_U_L": 33,
"creatinine_mg_dL": 0.85,
"date": "2024-12-28",
"hemoglobin_g_dL": 13.3,
"platelets_k_uL": 315,
"wbc_k_uL": 5
},
{
"alt_U_L": 28,
"creatinine_mg_dL": 1.08,
"date": "2025-07-25",
"hemoglobin_g_dL": 10.4,
"platelets_k_uL": 177,
"wbc_k_uL": 5.3
},
{
"alt_U_L": 129,
"creatinine_mg_dL": 1.76,
"date": "2026-07-31",
"hemoglobin_g_dL": 10.8,
"platelets_k_uL": 127,
"wbc_k_uL": 4.8
}
] | true
|
ANODE_SYNTH_2025_029
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IVB
|
{
"driver_mutation": "EGFR exon 19 deletion",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23,
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.9
}
|
{
"age": 82,
"bmi": 21.7,
"comorbidities": [
"diabetes"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 0
}
|
{
"brain_metastases_present": true,
"metastatic_sites": [
"pleura",
"bone",
"contralateral lung"
],
"primary_tumor_size_cm": 2.8,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
}
|
{
"first_line_therapy": {
"best_response": "Complete response",
"pfs_months": 34,
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -53
},
"regimen": "osimertinib 80 mg orally once daily",
"start_date": "2021-04-13"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2023-01-28",
"toxicity_grade": [
"none",
"Grade 2 fatigue"
],
"trigger_reason": "radiologic progression"
}
}
|
{
"censored": true,
"overall_survival_months": 28
}
|
[
{
"alt_U_L": 46,
"creatinine_mg_dL": 1.02,
"date": "2021-03-11",
"hemoglobin_g_dL": 13.3,
"platelets_k_uL": 348,
"wbc_k_uL": 10.1
},
{
"alt_U_L": 115,
"creatinine_mg_dL": 0.73,
"date": "2021-10-10",
"hemoglobin_g_dL": 11.5,
"platelets_k_uL": 372,
"wbc_k_uL": 4.6
},
{
"alt_U_L": 27,
"creatinine_mg_dL": 1.9500000000000002,
"date": "2023-01-28",
"hemoglobin_g_dL": 11.3,
"platelets_k_uL": 132,
"wbc_k_uL": 4.7
}
] | true
|
ANODE_SYNTH_2025_030
|
Non-small cell lung cancer
|
Adenocarcinoma
|
IV
|
{
"driver_mutation": "BRAF V600E",
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28,
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.5
}
|
{
"age": 76,
"bmi": 30.9,
"comorbidities": [
"none",
"COPD"
],
"ecog_performance_status": 1,
"sex": "female",
"smoking_pack_years": 10
}
|
{
"brain_metastases_present": false,
"metastatic_sites": [
"bone",
"liver"
],
"primary_tumor_size_cm": 2.8,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
}
|
{
"first_line_therapy": {
"best_response": "Complete response",
"pfs_months": 7,
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -59
},
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-06-15"
},
"second_line_therapy": {
"best_response": "Stable disease",
"regimen": "carboplatin (AUC5) + pemetrexed 500 mg/m² q21d + pembrolizumab",
"start_date": "2026-08-04",
"toxicity_grade": [
"Grade 3 neutropenia",
"none"
],
"trigger_reason": "symptomatic progression"
}
}
|
{
"censored": false,
"overall_survival_months": 95
}
|
[
{
"alt_U_L": 37,
"creatinine_mg_dL": 0.75,
"date": "2024-05-19",
"hemoglobin_g_dL": 15.4,
"platelets_k_uL": 151,
"wbc_k_uL": 10.7
},
{
"alt_U_L": 60,
"creatinine_mg_dL": 0.73,
"date": "2024-12-12",
"hemoglobin_g_dL": 11.3,
"platelets_k_uL": 302,
"wbc_k_uL": 7.2
},
{
"alt_U_L": 191,
"creatinine_mg_dL": 1.09,
"date": "2026-08-04",
"hemoglobin_g_dL": 11.5,
"platelets_k_uL": 204,
"wbc_k_uL": 4.7
}
] | true
|
README.md exists but content is empty.
- Downloads last month
- 7